The winter 2026 edition of our WRAP Newsletter is now available, offering a look at new research, program milestones, and team updates.
Claire Bitner
New policy proposal charts the future of early Alzheimer’s treatment
WRAP mPI Sterling Johnson, PhD, is co-author of a forthcoming Policy View in the March issue of The Lancet Neurology. The paper offers recommendations in Alzheimer’s disease treatment and prevention, with important considerations for treatments in people who are cognitively unimpaired but at risk of future symptoms.
Dr. Jessica Caldwell explores gender differences in Alzheimer’s disease as new WRAP study leader
Caldwell joined UW–Madison in September 2025 as the multi-principal investigator of the Wisconsin Registry for Alzheimer’s Prevention study
That’s a wrap!
Watch a recording and find details from the 2025 WRAP Info Sessions
UW–Madison Alzheimer’s disease researchers present new findings at 2025 international conference
More than 50 researchers from UW-Madison Alzheimer’s disease research programs joined thousands of global experts at the Alzheimer’s Association International Conference 2025 (AAIC), held July 27-July 31 in Toronto, Canada.
WRAP Info Sessions are back
The 2025 WRAP Info Sessions will be held Sept. 30 to Oct. 14 in multiple locations in Wisconsin: Neenah, Milwaukee, Madison, La Crosse
Two leading dementia researchers join UW–Madison
UW–Madison’s School of Medicine and Public Health is adding Henrik Zetterberg, a Swedish scientist who studies biomarkers, and Hartmuth Kolb, a German-born chemist and expert in imaging technology, to its faculty.
Read all about it: news from our study team in the latest WRAP newsletter
Keeping research participants informed about the study’s findings and work is one of the foundational priorities of the WRAP study. To help with that goal, the study team sends a printed newsletter to participants twice each year.
Dr. Nathaniel Chin discusses UW–Madison role in Alzheimer’s disease blood tests with regional media outlets
Nathaniel Chin, MD, medical director of the WRAP study, appeared on numerous Wisconsin news outlets to discuss the recent Food and Drug Administration (FDA) approval of a blood test for Alzheimer’s disease. The accuracy of the blood test was validated using data samples from the Wisconsin Alzheimer’s Disease Research Center (ADRC) and the Wisconsin Registry for Alzheimer’s Prevention (WRAP).
WRAP research helps launch first FDA-cleared blood test for Alzheimer’s
Data samples used to evaluate the validity of the test are from research conducted at the University of Wisconsin–Madison, including the Wisconsin Registry for Alzheimer’s Prevention.